| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $64.5M | +35.8% |
| SG&A Expense | $28.9M | +34.3% |
| Operating Income | -$93.4M | -35.4% |
| Net Income | -$92.1M | -33.7% |
| EPS (Basic) | -$2.33 | -11.0% |
| EPS (Diluted) | -$2.33 | -11.0% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $57.7M | -51.8% |
| Short-term Investments | $172.5M | +96.8% |
| Current Assets | $236.9M | +10.5% |
| Total Assets | $299.4M | +23.4% |
| Current Liabilities | $13.1M | +29.2% |
| Total Liabilities | $48.8M | +85.2% |
| Stockholders' Equity | $250.6M | +15.9% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$85.1M | -23.1% |
| Capital Expenditures | $8.5M | +117.3% |
| Investing Cash Flow | -$94.1M | -2.7% |
| Financing Cash Flow | $117.1M | -49.7% |
| Free Cash Flow | -$93.6M | -28.2% |